Overview of emerging pharmacologic agents for acute heart failure syndromes

European Journal of Heart Failure

Volumn 10, Issue 2, 2008, Pages 201-213

  De Luca, Leonardo ^a   Mebazaa, Alexandre ^b   Filippatos, Gerasimos ^c   Parissis, John T ^d   Böhm, Michael ^e   Voors, Adriaan A ^f   Nieminen, Markku ^g   Zannad, Faiez ^h   Rhodes, Andrew ⁱ   El Banayosy, Ali ^j   Dickstein, Kenneth ^k   Gheorghiade, Mihai ^l  

^a EUROPEAN HOSPITAL   (Italy)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITY OF ATHENS   (Greece)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h INSERM   (France)

ⁱ ST GEORGE S HOSPITAL   (United Kingdom)

^j RUHR UNIVERSITY BOCHUM   (Germany)

^k UNIVERSITY OF BERGEN   (Norway)

^l NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Acute heart failure; New medical treatment

Indexed keywords

3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; ADENOSINE RECEPTOR BLOCKING AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; DARUSENTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; GLUCOSE; GLYCERYL TRINITRATE; LEVOSIMENDAN; MILRINONE; MYOSIN; NAXIFYLLINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; TEZOSENTAN; TOLVAPTAN; UNINDEXED DRUG; URODILATIN; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; ADD ON THERAPY; CARDIOPULMONARY FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LONG TERM CARE; LUNG CONGESTION; MONOTHERAPY; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THIRST; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADENOSINE; CARDIOVASCULAR AGENTS; ENDOTHELIN-1; ETIOCHOLANOLONE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; NATRIURETIC PEPTIDE, BRAIN; PERHEXILINE; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-POTASSIUM-EXCHANGING ATPASE; SYNDROME; VASODILATOR AGENTS;

EID: 38949156223     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.01.002     Document Type: Review

References (100)

1. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
2. Gheorghiade M., Abraham W., Albert N., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
3. Filippatos G., and Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev 12 (2007) 87-90
4. Shin D.D., Brandimarte F., De Luca L., et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99 (2007) 4A-23A
5. Bayram M., De Luca L., Massie M.B., and Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96 (2005) 47-58
6. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
7. Hasselblad V., Stough W.G., Shah M.R., et al. Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial [abstract]. J Card Fail 11 (2005) S157
8. Cohn J.N., Franciosa J.A., Francis G.S., et al. Effect of shortterm infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 306 (1982) 1129-1135
9. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., and Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305 (1981) 263-266
10. Riegger G.A.J., Liebau G., and Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 72 (1982) 49-52
11. Schrier R.W., and Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med 341 (1999) 577-585
12. Klein L., O'Connor C.M., Leimberger J.D., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111 (2005) 2454-2460
13. Gheorghiade M., Abraham W.T., Albert N.M., et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 28 (2007) 980-988
14. Gheorghiade M., Rossi J.S., Cotts W., et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 167 (2007) 1998-2005
15. Goldsmith S.R. Vasopressin: a therapeutic target in congestive heart failure?. J Card Fail 5 (1999) 347-356
16. Udelson J.E., Smith W.B., Hendrix G.H., et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
17. Gheorghiade M., Niazi I., Ouyang J., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
18. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
19. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
20. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
21. Udelson J.E., McGrew F.A., Flores E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49 (2007) 2151-2159
22. Modlinger P.S., and Welch W.J. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12 (2003) 497-502
23. Gottlieb S.S. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs 61 (2001) 1387-1393
24. Givertz M.M., Massie B.M., Fields T.K., Pearson L.L., Dittrich H.C., and CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50 (2007) 1551-1560
25. Dittrich H.C., Gupta D.K., Hack T.C., et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 13 (2007) 609-617
26. Gottlieb S.S., Skettino S.L., Wolff A., et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 35 (2000) 56-59
27. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
28. Greenberg B., Thomas I., Banish D., et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 50 (2007) 600-606
29. Kalk P., Eggert B., Relle K., et al. The adenosine A(1) receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol. 151 (2007) 1025-1032
30. Metra M., and Cotter G. Placebo-controlled randomized study of the selective A1 adenosine receptor antagonist KW-3902 for patients hospitalized with acute HF and volume Overload to assess Treatment Effect on Congestion and renal funcTion (PROTECT) pilot study. Late-breaking Clinical Trials. Heart Failure Congress, Annual Meeting, Hamburg, Germany (June 2007) 9-12
31. Liao Y., Takashima S., Asano Y., et al. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 93 (2003) 759-766
32. Forssmann W., Meyer M., and Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 51 (2001) 450-462
33. Kentsch M., Ludwig D., Drummer C., Gerzer R., and Muller-Esch G. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 22 (1992) 662-669
34. Elsner D., Muders F., Muntze A., Kromer E.P., Forssmann W.G., and Riegger G.A. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am Heart J 129 (1995) 766-773
35. Mitrovic V., Luss H., Nitsche K., et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 150 (2005) 1239
36. Mitrovic V., Seferovic P.M., Simeunovic D., et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27 (2006) 2823-2832
37. Teerlink J.R. The role of endothelin in the pathogenesis of heart failure. Curr Cardiol Rep 4 (2002) 206-212
38. Aronson D., and Burger A.J. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure role of endothelin. PACE Pacing Clin Electrophysiol 26 (2003) 703-710
39. Aronson D., and Burger A.J. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol 91 (2003) 245-248
40. Gheorghiade M., De Luca L., and Bonow R.O. Neurohormonal Inhibition in heart failure: insights from recent clinical trials. Am J Cardiol 96 suppl (2005) 3L-9L
41. Teerlink J.R., Massie B.M., Cleland J.G.F., Tzivoni D., and for the RITZ-1 Investigators. A double-blind, parallel-group, multi-center, placebocontrolled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure [abstract]. Circulation 104 (2001) II-526
42. Torre-Amione G., Young J.B., Colucci W.S., et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42 (2003) 140-147
43. O'Connor C.M., Gattis W.A., Adams Jr. K.F., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41 (2003) 1452-1457
44. Kaluski E., Kobrin I., Zimlichman R., et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41 (2003) 204-210
45. McMurray J.J., Terlink J., Cotte G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007) 2009-2019
46. Abraham W.T., Adams Jr. K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46 (2005) 57-64
47. Micheletti R., Mattera G.G., Rocchetti M., et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303 (2002) 592-600
48. De Munari S., Cerri A., Gobbini M., et al. Structure based design and synthesis of novel potent Na+/K+-ATPase inhibitors derived from a 5α,14 α-androstane scaffold as positive inotropic compounds. J Med Chem 56 (2003) 3644-3654
49. Rocchetti M., Besana A., Mostacciuolo G., Ferrari P., Micheletti R., and Zaza A. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms. J Pharmacol Exp Ther 305 (2003) 765-771
50. Rocchetti M., Besana A., Mostacciuolo G., et al. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther 313 (2005) 207-215
51. Adamson P.B., Vanoli E., Mattera G.G., et al. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 42 (2003) 169-173
52. Barassi P., Ferrandi M., Bianchi G., and Ferrari P. Istaroxime stimulates SERCA2a activity in animal and human failing heart preparations [abstract]. J Card Fail 11 (2005) S154
53. Mattera G.G., Lo Giudice P., Loi F.M.P., et al. Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol 99 (2007) S33-S40
54. Sabbah H.N., Imai M., Cowart D., Amato A., Carminati P., and Gheorghiade M. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 99 (2007) S41-S46
55. Ghali J.K., Smith W.B., Torre-Amione G., et al. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 99 (2007) S47-S56
56. Cleland J.G., Coletta A.P., and Clark A.L. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail 8 (2006) 764-766
57. Niu C, Anderson R, Cox D, et al. The cardiac myosin activator, CK-1122534, increases contractility in adult cardiac myocytes without altering the calcium transient. Presented at the 44th Annual Meeting of the American Society of Cell Biology; December 4-8, 2004; Washington, DC.
58. Malik F, Elias KA, Finer JT, et al. Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. Presented at the 9th Annual Scientific Meeting of the Heart Failure Society of America; September 18-21, 2005; Boca Raton, Florida.
59. Anderson RL, Sueoka SH, Rodriguez HM, et al. In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. Presented at the 45th Annual Meeting of the American Society of Cell Biology; December 10-14, 2005; San Francisco, California.
60. Niu C, Cox D, Lee K, et al. Cellular responses of the myosin activator CK-0689705 in normal and heart failure models. Presented at the 44th Annual Meeting of the American Society of Cell Biology; December 4-8, 2004; Washington, DC.
61. Stanley W.C., Lopaschuk G.D., Hall J.L., and McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res 33 (1997) 243-257
62. Taegtmeyer H., Roberts A.F., and Raine A.E. Energy metabolism in reperfused heart muscle: metabolic correlates to return of function. J Am Coll Cardiol 6 (1985) 864-870
63. Depre C., Vanoverschelde J.L., and Taegtmeyer H. Glucose for the heart. Circulation 99 (1999) 578-588
64. Lopaschuk G.D., Wambolt R.B., and Barr R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264 (1993) 135-144
65. Murnaghan M.F. Effect of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit. Br J Pharmacol 73 (1981) 909-915
66. Kennedy J.A., Kiosoglous A.J., Murphy G.A., Pelle M.A., and Horowitz J.D. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 36 (2000) 794-801
67. Cole P.L., Beamer A.D., McGowan N., et al. Efficacy and safety of perhexiline maleate in refractory angina. Circulation 81 (1990) 1260-1270
68. Treasure C.B., Vita J.A., Cox D.A., et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81 (1990) 772-779
69. Unverferth D.V., Magorien R.D., Lewis R.P., and Leier C.V. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 105 (1983) 176-179
70. van den Heuvel A.F., van Veldhuisen D.J., van der Wall E.E., et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35 (2000) 19-28
71. Kupari M., Mikkola T.S., Turto H., and Lommi J. Is the pregnancy hormone relaxin an important player in human heart failure?. Eur J Heart Fail 7 (2005) 195-198
72. Dschietzig T., Richter C., Bartsch C., et al. The pregnancy hormone relaxin is a player in human heart failure. Faseb J 15 (2001) 2187-2195
73. Fisher C., Berry C., Blue L., Morton J.J., and McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89 (2003) 879-881
74. Barry W.H., Horowitz J.D., and Smith T.W. Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Pharmacol 85 (1985) 51-59
75. Jeffrey F.M., Alvarez L., Diczku V., Sherry A.D., and Malloy C.R. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 25 (1995) 469-472
76. Horowitz J.D., and Mashford M.L. Perhexiline maleate in the treatment of severe angina pectoris. Med J Aust 1 (1979) 485-488
77. Roberts R.K., Cohn D., Petroff V., and Seneviratne B. Liver disease induced by perhexiline maleate. Med J Aust 2 (1981) 553-554
78. Bouche P., Bousser M.G., Peytour M.A., and Cathala H.P. Perhexiline maleate and peripheral neuropathy. Neurology 29 (1979) 739-743
79. Lee L., Campbell R., Scheuermann-Freestone M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112 (2005) 3280-3288
80. Mills R.M., LeJemtel T.H., Horton D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 34 (1999) 155-162
81. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
82. Publication Committee for the VMAC [Vasodilatation in the Management of Acute CHF] Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
83. Topol E.J. Nesiritide-not verified. N Engl J Med 353 (2005) 113-116
84. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
85. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
86. Aaronson K.D., and Sackner-Bernstein J.D. Risk of death associated with nesiritide in patients with acutely decompensated heart failure [research letter]. JAMA 296 (2006) 1465-1466
87. Witteles R.M., Kao D., Christopherson D., et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 50 (2007) 1835-1840
88. Cleland J.G., Coletta A.P., and Clark A.L. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 9 (2007) 740-745
89. Parissis J.T., Farmakis D., and Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 12 (2007) 149-156
90. De Luca L., Colucci W.S., Nieminen M.S., Massie B.M., and Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27 (2006) 1908-1920
91. Parissis J., Filippatos G., Farmakis D., Adamopoulos S., Paraskevaidis I., and Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Exp Opin Pharmacother 6 15 (2005) 2741-2751
92. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1903-1912
93. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102 (2000) 2222-2227
94. Parissis J., Panou F., Famakis D., et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96 (2005) 423-426
95. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
96. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 360 (2002) 196-202
97. Packer M., Colucci W.S., and Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study (Abstract). J Card Fail 9 (2003) S61
98. Packer M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials (November 2005), American Heart Association, Annual Scientific Session, Dallas, TX 13-16
99. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297 (2007) 1883-1891
100. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The task force on acute heart failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416